LRMR Live signals | Maximize Profits with Getagraph.com

BUY 126714 min ago

@ $11.62

Issued: 14 Feb 2024 @ 13:41

Return: -38.70%

Previous signal: Feb 13 - 15:50

Previous signal: Sell

Return: 25.70 %

Live Chart Being Loaded With Signals

Commentary (10 May 2024 @ 16:00):

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform...

Stats
Today's Volume	362 529
Average Volume	613 472
Market Cap	454.26M
EPS	$0 ( 2024-03-12 )
Next earnings date	( $-0.240 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-8.48
ATR14	$0.0160 (0.22%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-16	Flynn James E	Buy	1 430 206	Common Stock
2024-02-16	Flynn James E	Buy	1 430 206	Common Stock
2024-02-16	Flynn James E	Buy	1 430 205	Common Stock
2024-02-14	Thomas Frank E	Buy	2 000	Common Stock
2024-01-17	Shankar Gopi	Buy	135 000	Stock Option (Right to Buy)

INSIDER POWER
100.00
Last 91 transactions
Buy: 20 937 267 \| Sell: 6 152 661

Volume Correlation

Long: -0.29 (neutral)

Short: -0.76 (moderate negative)

Signal:(39.127) Neutral

Larimar Therapeutics Inc Correlation

10 Most Positive Correlations
FAT	0.921
NSSC	0.919
ADVM	0.91
SRTS	0.894
TYRA	0.886
LXRX	0.881
MORF	0.879
ADP	0.873
PCVX	0.871
ADRE	0.861

10 Most Negative Correlations
CINC	-0.867
GIPR	-0.829
MFNC	-0.829
BFRI	-0.825
RTPY	-0.818

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Larimar Therapeutics Inc Correlation - Currency/Commodity

-0.41
( neutral )

-0.46
( neutral )

0.00
( neutral )

-0.27
( neutral )

0.53
( weak )

Larimar Therapeutics Inc Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-311 000 (0.00 %)
EPS:	$-0.840

FY	2023
Revenue:	$0
Gross Profit:	$-311 000 (0.00 %)
EPS:	$-0.840

FY	2022
Revenue:	$0
Gross Profit:	$-272 000 (0.00 %)
EPS:	$-1.330

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-4.26

Financial Reports:

No articles found.

Larimar Therapeutics Inc

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.